Oncolytics Biotech Inc represents values of innovation, dedication, and patient-centricity. With a corporate philosophy focused on developing targeted and cutting-edge therapies, Oncolytics Biotech is committed to advancing the field of oncolytic viruses for the treatment of cancer. The company's research and development efforts aim to provide patients with safe and effective treatments that harness the power of viruses to selectively destroy cancer cells while sparing healthy tissue. By constantly pushing the boundaries of science and seeking collaborations with experts in the field, Oncolytics Biotech strives to improve outcomes and quality of life for patients worldwide.

Oncolytics Biotech Inc is primarily present in Canada and the United States.

Oncolytics Biotech Inc has achieved several significant milestones in its journey. The company successfully received FDA Fast Track Designation for its lead product candidate, REOLYSIN, which is being developed for the treatment of metastatic breast cancer. Oncolytics Biotech also obtained Orphan Drug Designation for REOLYSIN from the FDA for the treatment of pancreatic cancer. Additionally, the company has entered into various strategic collaborations and partnerships to advance its oncology research and development initiatives. These achievements highlight Oncolytics Biotech's commitment to bringing innovative treatments to patients, particularly in the field of cancer therapy.

Oncolytics Biotech Inc is a renowned biotechnology company specializing in the development of innovative cancer therapeutics. Founded in 1998, the company has a rich history and is headquartered in Calgary, Canada. Oncolytics Biotech focuses on harnessing the power of viruses to selectively target and destroy cancer cells without harming healthy tissues. Their flagship product, REOLYSIN®, is a proprietary formulation of the reovirus, which has shown promising results in clinical trials for a variety of cancer types. The company's dedication to research and development has positioned them as a leader in the field of oncolytic viruses, offering hope for effective cancer treatments in the future.

The main competitors of Oncolytics Biotech Inc in the market include companies like Amgen Inc., Roche Holding AG, and Pfizer Inc.

Oncolytics Biotech Inc primarily operates in the biotechnology industry.

The business model of Oncolytics Biotech Inc revolves around developing and commercializing immune-oncology virus-based therapies for the treatment of cancer. By utilizing its proprietary platform technology, the company aims to target and destroy cancer cells without harming normal healthy cells. Oncolytics Biotech's innovative approach involves using genetically modified viruses to selectively infect and replicate within cancer cells, resulting in their destruction. This targeted therapy is designed to stimulate the immune system's response to better fight against cancer cells. Oncolytics Biotech Inc's business model focuses on advancing its therapy candidates through clinical trials, seeking regulatory approvals, and ultimately providing effective treatments to cancer patients.

Oncolytics Biotech Коефіцієнт P/E становить -2,29.

Коефіцієнт виручки від продажу Oncolytics Biotech становить 0.

АлеАкції індекс якості для Oncolytics Biotech складає 3/10.

Дохід зараз не можна розрахувати для Oncolytics Biotech.

очікувана Oncolytics Biotech прибуток становить -30,98 млн. CAD.

Oncolytics Biotech is a Canadian company specializing in the development of virotherapeutic treatments for cancer. The company uses specially modified viruses to selectively destroy cancer cells. Oncolytics Biotech operates in the areas of research, development, manufacturing, and marketing. Its main product line is REOLYSIN®, an oncolytic virus that targets and destroys cancer cells in the body. The company aims to expand its portfolio of oncolytic viruses through continuous research and development projects. It collaborates with universities and research institutions worldwide to access important insights and advancements in cancer research. Oncolytics Biotech distributes and markets its biopharmaceutical products primarily through partnerships with pharmaceutical companies both domestically and internationally. The company has also carried out a strategic acquisition of TMG Biosciences to enhance its research capabilities and expand its oncolytic virus portfolio. Overall, Oncolytics Biotech's mission is to defeat cancer through innovative therapeutic approaches, offering a promising new therapy option for cancer patients worldwide.

Oncolytics Biotech виплачує дивіденд у розмірі 0 CAD, розподілений на виплати протягом року.

Дивіденди для Oncolytics Biotech на даний момент не можуть бути розраховані, або компанія не виплачує дивіденди.

ISIN Oncolytics Biotech є CA6823108759.

WKN Oncolytics Biotech становить A2JMW5.

Тікер Oncolytics Biotech це ONC.TO.

Протягом останніх 12 місяців компанія Oncolytics Biotech виплатила дивіденд у розмірі . Це відповідає приблизній дивідендній дохідності . Очікується, що протягом наступних 12 місяців Oncolytics Biotech виплатить дивіденд у розмірі 0 CAD.

Дивідендна дохідність Oncolytics Biotech наразі становить .

Oncolytics Biotech виплачує дивіденди щоквартально. Вони виплачуються у місяцях .

Oncolytics Biotech протягом останніх 0 років щороку виплачував дивіденди.

На наступні 12 місяців очікується дивіденди у розмірі 0 CAD. Це відповідає дивідендній дохідності 0 %.

Oncolytics Biotech призначається до сектора "Здоров'я".

Щоб отримати останній дивіденд від Oncolytics Biotech від 25.09.2024 у розмірі 0 CAD, тобі потрібно було мати акцію в портфелі до дня Ex-Tag 25.09.2024.

Останню дивіденду було виплачено 25.09.2024.

У 2023 році компанія Oncolytics Biotech виплатила 0 CAD у вигляді дивідендів.

Дивіденди Oncolytics Biotech виплачуються у CAD.